Lv1
90 积分 2022-08-03 加入
The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy
4天前
已完结
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview
5天前
已完结
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
19天前
已完结
MA04.03 Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A EGFR Mutated NSCLC With High Risk (APPOINT)
19天前
已完结
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
23天前
已完结
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
23天前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
26天前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
28天前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
28天前
已完结
Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes
1个月前
已关闭
皖公网安备34019202002308
